SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Young David – ‘4’ for 1/1/24 re: Processa Pharmaceuticals, Inc.

On:  Friday, 4/12/24, at 5:01pm ET   ·   For:  1/1/24   ·   As:  Director and Officer   ·   Accession #:  897069-24-925   ·   File #:  1-39531

Previous ‘4’:  ‘4’ on 2/8/24 for 2/7/24   ·   Latest ‘4’:  This Filing

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/12/24  Young David                       4          Dir.,Off.   1:8K   Processa Pharmaceuticals, Inc.    Foley & Lardner/FA

Statement of Changes in Beneficial Ownership of Securities by an Insider   —   Form 4   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 4           Statement of Changes in Beneficial Ownership of     HTML      9K 
                Securities by an Insider -- form4.xml/5.8


        

This ‘4’ Document is an XML Data File that may be rendered in various formats:

  Form 4    –   Plain Text   –  SEC Website  –  EDGAR System  –    XML Data    –  <?xml?> File
 
 
SEC Info℠ rendering:  Statement of Changes in Beneficial Ownership of Securities by an Insider
 

The SEC has not released XSLT Stylesheets needed to render this File’s XML Data as a Form.

This is our “Plain Text” rendering:
 
                                                                                                                                                                                
Ownership Document
 
Schema Version:  X0508
Document Type:  4
Period of Report:  1/1/24
Issuer:
Issuer CIK:  1533743
Issuer Name:  Processa Pharmaceuticals, Inc.
Issuer Trading Symbol:  PCSA
Reporting Owner:
Reporting Owner ID:
Owner CIK:  1378166
Owner Name:  Young David
Reporting Owner Address:
Owner Street 1:  C/O PROCESSA PHARMACEUTICALS, INC.
Owner Street 2:  7380 COCA COLA DRIVE, SUITE 106
Owner City:  HANOVER
Owner State:  MD
Owner ZIP Code:  21076
Owner State Description:
Reporting Owner Relationship:
Is Director?  Yes
Is Officer?  Yes
Officer Title:  Pres. Research & Development
Aff 10b5 One?  No
Non-Derivative Table:
Non-Derivative Transaction:
Security Title:
Value:  Common Stock
Transaction Date:
Value:  1/1/24
Transaction Coding:
Transaction Form Type:  4
Transaction Code:  M
Equity Swap Involved?  No
Transaction Amounts:
Transaction Shares:
Value:  1,675
Transaction Price Per Share:
Footnote ID:  F1
Transaction Acquired-Disposed Code:
Value:  A
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  81,062
Footnote ID:  F2
Ownership Nature:
Direct or Indirect Ownership:
Value:  D
Non-Derivative Transaction:
Security Title:
Value:  Common Stock
Transaction Date:
Value:  1/1/24
Transaction Coding:
Transaction Form Type:  4
Transaction Code:  F
Equity Swap Involved?  No
Transaction Amounts:
Transaction Shares:
Value:  518
Transaction Price Per Share:
Value:  2.79
Transaction Acquired-Disposed Code:
Value:  D
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  80,544
Footnote ID:  F2
Ownership Nature:
Direct or Indirect Ownership:
Value:  D
Non-Derivative Holding:
Security Title:
Value:  Common Stock
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  30,985
Footnote ID:  F2
Ownership Nature:
Direct or Indirect Ownership:
Value:  I
Nature of Ownership:
Value:  By Young-Plaisance Revocable Trust
Non-Derivative Holding:
Security Title:
Value:  Common Stock
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  10,786
Footnote ID:  F2
Ownership Nature:
Direct or Indirect Ownership:
Value:  I
Nature of Ownership:
Value:  By Family Entities
Non-Derivative Holding:
Security Title:
Value:  Common Stock
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  18,544
Footnote ID:  F2
Ownership Nature:
Direct or Indirect Ownership:
Value:  I
Nature of Ownership:
Value:  By CorLyst, LLC
Derivative Table:
Derivative Transaction:
Security Title:
Value:  Restricted Stock Units
Conversion or Exercise Price:
Value:  0
Transaction Date:
Value:  1/1/24
Transaction Coding:
Transaction Form Type:  4
Transaction Code:  M
Equity Swap Involved?  No
Transaction Amounts:
Transaction Shares:
Value:  1,675
Transaction Price Per Share:
Value:  0
Transaction Acquired-Disposed Code:
Value:  D
Exercise Date:
Footnote ID:  F1
Expiration Date:
Footnote ID:  F1
Underlying Security:
Underlying Security Title:
Value:  Common Stock
Underlying Security Shares:
Value:  1,675
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  19,333
Footnote ID:  F2
Ownership Nature:
Direct or Indirect Ownership:
Value:  D
Footnotes:
Footnote - F1:  Distribution of vested restricted shares.
Footnote - F2:  Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
Owner Signature:
Signature Name:  /s/ David Young by Michael B. Kirwan, as Attorney-in-Fact
Signature Date:  4/12/24


↑Top
Filing Submission 0000897069-24-000925   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., May 2, 2:57:38.1am ET